⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 3, 2024Open Access

Supplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas

Federico Stella Annalisa Chiappella Beatrice Casadei Stéfania Bramanti Silva Ljevar Patrizia Chiusolo Alice Di Rocco Maria Chiara Tisi Matteo Giovanni Carrabba Ilaria Cutini Massimo Martino Anna Dodero Francesca Bonifazi Armando Santoro Federica Sorà Barbara Botto Anna M. Barbui Domenico Russo Maurizio Musso Giovanni Grillo Mauro Krampera Jacopo Olivieri Marco Ladetto Federica Cavallo Massimo Massaia Luca Arcaini Martina Pennisi Pier Luigi Zinzani Rosalba Miceli Paolo Corradini

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stella et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db6435875339f1 https://doi.org/10.1158/2643-3230.26926050.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024
2Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024
3Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024
4Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024
5Data from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024

More related papers

A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas2024
Comparative efficacy and toxicity of Axicabtagene Ciloleucel <i>versus</i> Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis2026
Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma2026